S.A. Cellectis Net Worth

The estimated Net Worth of S.A. Cellectis is at least $143 Million dollars as of 15 June 2018. S Cellectis owns over 63,175 units of Calyxt Inc stock worth over $143,093,003 and over the last 6 years S sold CLXT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

S Cellectis CLXT stock SEC Form 4 insiders trading

S has made over 1 trades of the Calyxt Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently S bought 63,175 units of CLXT stock worth $1,231,281 on 15 June 2018.

The largest trade S's ever made was buying 63,175 units of Calyxt Inc stock on 15 June 2018 worth over $1,231,281. On average, S trades about 21,058 units every 0 days since 2018. As of 15 June 2018 S still owns at least 22,713,175 units of Calyxt Inc stock.

You can see the complete history of S Cellectis stock trades at the bottom of the page.

What's S Cellectis's mailing address?

S's mailing address filed with the SEC is 8 Rue de la Croix Jarry, 75013 Paris, France.

Insiders trading at Calyxt Inc

Over the last 7 years, insiders at Calyxt Inc have traded over $2,578,214 worth of Calyxt Inc stock and bought 116,475 units worth $1,447,167 . The most active insiders traders include Kimberly K. Nelson, Daniel F Voytas, and Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of $35,853. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth $7,200.

What does Calyxt Inc do?

Complete history of S Cellectis stock trades at Calyxt Inc

Calyxt Inc executives and stock owners

Calyxt Inc executives and other stock owners filed with the SEC include:

• James Blome,
  Chief Executive Officer, Director
• William Koschak,
  Chief Financial Officer
• Debra Frimerman,
  General Counsel
• Kimberly Nelson,
  Independent Director
• William F. Koschak,
  Chief Financial Officer
• Dr. Travis J. Frey Ph.D.,
  Chief Technology Officer
• Daniel Voytas,
  Chief Scientific Officer
• Philippe Dumont,
  Independent Director
• Yves Ribeill,
  Chairman of the Board
• Christopher Neugent,
  Independent Director
• Anna Kozicz-Stankiewicz,
  Independent Director
• Jonathan Fassberg,
  Independent Director
• Chris Tyson,
  IR Contact Officer
• Laurent Arthaud,
  Director
• Bobby Williams,
  Director - Gene Editing
• Vince Restucci,
  Vice President of Agronomy Services
• Sarah Reiter,
  Vice President - Business Development
• Travis Frey,
  Chief Technology Officer
• Keith Blanks,
  Senior Vice President of Sales and Marketing
• Gerry Nuovo,
  Sr. VP of Bus. Devel.
• Dr. Stephen M. Bravo,
  Chief Medical Officer
• Trina Lundblad,
  Director of Communications
• Debra H. Frimerman,
  Gen. Counsel & Corp. Sec.
• Dr. Daniel F. Voytas Ph.D.,
  Founder, Chief Science Officer & Chair of Scientific Advisory Board
• Michael Allen Carr,
  Pres, CEO & Director
• Michael A. Carr,
  President and CEO
• Manoj Sahoo,
  Chief Commercial Officer
• Alain Godard,
  Director
• Bryan W.J. Corkal,
  Chief Financial Officer
• Michel Arbadji,
  Director of Business Developme
• Federico A. Tripodi,
  Chief Executive Officer
• Glenn R Bowers,
  Vice President of Breeding
• S.A. Cellectis,
  10% owner